Loading
A phase 1 trial of MRTX1133 in Non-small-cell lung cancer and Rectal cancer, run by Mirati Therapeutics Inc., recorded as terminated on the registry.
Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation is a phase 1 interventional study registered as NCT05737706 by Mirati Therapeutics Inc., with 63 participants recorded, started 2023-03-06 and due to reach its primary completion in 2025-03-10. Interventions recorded: MRTX1133. Conditions recorded: Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, Colo-rectal Cancer, Pancreatic Adenocarcinoma.
Linked to the drug MRTX1133 because the registry names it among its interventions and Non-small-cell lung cancer and Rectal cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Bristol Myers Squibb, Non-small-cell lung cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Bristol Myers Squibb, Non-small-cell lung cancer and the tag pipeline.
Shares Bristol Myers Squibb, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Bristol Myers Squibb, Non-small-cell lung cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.